Previous 10 | Next 10 |
The following slide deck was published by Albireo Pharma, Inc. in conjunction with this event. For further details see: Albireo Pharma (ALBO) Investor Presentation - Slideshow
Albireo Pharma (ALBO) announces new data in progressive familial intrahepatic cholestasis ((PFIC)) confirming statistically significant reductions in serum bile acids (sBAs) and improvements in pruritus for odevixibat, a potent, once-daily, non-systemic ileal bile acid transport inhibitor (IB...
- PEDFIC 1 meets both U . S . and EU primary and secondary endpoints with high ly statistically significant reductions in serum bile acids and pruritus - - Interim results from long-term exte...
BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present via webcast at the 2020 Jefferies London Hea...
Albireo Pharma (ALBO): Q3 GAAP EPS of -$1.96 misses by $0.45.Revenue of $2.13M (+53.2% Y/Y) beats by $0.5M.Press Release For further details see: Albireo Pharma EPS misses by $0.45, beats on revenue
- P ositive P hase 3 d ata for o devixibat in PFIC with filings on track for no later than early 202 1 - - Phase 3 PFIC data accepted as late breakers at upcoming AASLD Meeting - - Introd...
- Final PEDFIC 1 and interim PEDFIC 2 results accepted at AASLD’s The Liver Meeting 2020 - - PEDFIC 1 and PEDFIC 2 : largest global Phase 3 in children with PFIC types 1, 2 & 3 - - T...
- Research continues to show potential of odevixibat as first drug therapy for PFIC and in other rare liver diseases- - Scientific leadership demonstrate s c ompany’s commitment to increase understanding of rare pedi...
Tracking insider purchases is an overlooked but very informative strategy. It can provide undervalued stocks in the market and can make assumptions for future market returns. September's number of insider purchases was close to the historical average, indicating that insiders are not ...
BOSTON, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2020, a global effor...
News, Short Squeeze, Breakout and More Instantly...
Albireo Pharma Inc. Company Name:
ALBO Stock Symbol:
NASDAQ Market:
Bylvay (odevixibat) granted Priority Review by U.S. FDA ASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patients Approval in second indication would more than double Bylvay market oppo...
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca , while Albireo Pharma (NASDAQ: ALBO) is set to be owned by ...
The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morni...